Alps Advisors Inc. raised its stake in Celldex Therapeutics Inc. (NASDAQ:CLDX) by 24.9% during the second quarter, Holdings Channel reports. The firm owned 138,680 shares of the biopharmaceutical company’s stock after buying an additional 27,677 shares during the period. Alps Advisors Inc.’s holdings in Celldex Therapeutics were worth $609,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the company. Bank of Montreal Can purchased a new position in Celldex Therapeutics during the second quarter valued at approximately $188,000. Canada Pension Plan Investment Board boosted its position in Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 33,800 shares during the period. Marcus Capital LLC boosted its position in Celldex Therapeutics by 45.3% in the first quarter. Marcus Capital LLC now owns 70,400 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 21,950 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Celldex Therapeutics by 2.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 70,903 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 1,412 shares during the period. Finally, Benchmark Capital Advisors boosted its position in Celldex Therapeutics by 259.8% in the first quarter. Benchmark Capital Advisors now owns 72,500 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 52,350 shares during the period. Hedge funds and other institutional investors own 78.41% of the company’s stock.
Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) traded up 6.32% during midday trading on Friday, hitting $4.04. 2,570,522 shares of the company traded hands. Celldex Therapeutics Inc. has a 12-month low of $2.96 and a 12-month high of $18.62. The stock’s market capitalization is $406.20 million. The stock’s 50-day moving average is $3.77 and its 200 day moving average is $4.13.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative net margin of 2,383.60% and a negative return on equity of 47.59%. The firm earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. During the same period last year, the firm posted ($0.33) EPS. The firm’s quarterly revenue was down 36.4% on a year-over-year basis. On average, analysts expect that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current year.
Several research analysts have recently issued reports on the stock. Cowen and Company reiterated an “outperform” rating and issued a $12.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, June 7th. Jefferies Group increased their price objective on shares of Celldex Therapeutics to $5.00 and gave the company a “hold” rating in a report on Friday, August 5th. Finally, Wedbush reiterated a “neutral” rating and issued a $3.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, August 9th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $10.75.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.